Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.38 |
| ▸ | USP10 | Q14694 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | USP13 | Q92995 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373276 | 1.00 | CDK8 (0.49) | CDK8CCNCPARP1GAKSLC22A12 | |
| SCHEMBL30976613 | 0.98 | CDK8 (0.47) | CDK8CCNCPARP1GAKSLC22A12 | |
| SCHEMBL16010398 | 0.84 | FERMT2 (0.49) | CDK8CCNCGAKCYP11B2FERMT2 | |
| SCHEMBL16705385 | 0.80 | CDK8 (0.49) | CDK8CCNCPARP1GAKSLC22A12 | |
| SCHEMBL14690611 | 0.79 | SLC22A12 (0.51) | CDK8CCNCGAKSLC22A12MAPT | |
| SCHEMBL29896761 | 0.79 | SLC22A12 (0.51) | CDK8CCNCGAKSLC22A12MAPT | |
| SCHEMBL2170635 | 0.78 | PRKCI (0.38) | CDK8CCNCSLC22A12IDO1KDR | |
| SCHEMBL25398078 | 0.76 | MAPT (0.46) | PARP1SLC22A12PRKCIKDM4EMAPT | |
| SCHEMBL15057041 | 0.76 | ESR1 (0.50) | PARP1KDRPRKCIKDM4EMAPT | |
| SCHEMBL20733040 | 0.76 | PARP1 (0.44) | CDK8CCNCPARP1GAKSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| EP-3753926-B1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024125668-A1 | HETEROCYCLIC SUBSTITUTED PENTA-SIX-MEMBERED HETEROARYL DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION AND PREPARATION METHOD THEREFOR | 上海海雁医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| EP-3686196-B1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4251149-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2008152603-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-12-18 | — | — | WO | disclosed |
| EP-1996579-A2 | ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007105154-A2 | ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
| EP-1539133-B1 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1549156-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | Investigacion Y Nutricion, S.L. (ES) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004014361-A9 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004014150-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | INVESTIGACION Y NUTRICION, S.L. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | CDK8 4053/4885CCNC 2952/4885PARP1 2872/4885 |
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | CDK8 2957/4885CCNC 3331/4885PARP1 2154/4885 |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | QARS1, NQO2, AAAS | CDK8 1102/4885CCNC 981/4885PARP1 771/4885 |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | CDK8 1868/4885CCNC 3887/4885PARP1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.